EP0620819A1 - Agents antiparasitaires - Google Patents

Agents antiparasitaires

Info

Publication number
EP0620819A1
EP0620819A1 EP92923776A EP92923776A EP0620819A1 EP 0620819 A1 EP0620819 A1 EP 0620819A1 EP 92923776 A EP92923776 A EP 92923776A EP 92923776 A EP92923776 A EP 92923776A EP 0620819 A1 EP0620819 A1 EP 0620819A1
Authority
EP
European Patent Office
Prior art keywords
group
oximino
compound according
optionally substituted
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92923776A
Other languages
German (de)
English (en)
Inventor
Stephen Paul Gibson
David Austen Perry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Ltd
MTG Divestitures LLC
Original Assignee
Pfizer Ltd
Pfizer Hospital Products Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd, Pfizer Hospital Products Group Inc filed Critical Pfizer Ltd
Publication of EP0620819A1 publication Critical patent/EP0620819A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Definitions

  • This invention relates to antiparasitic agents, related to the milbe ycins and to processes for their preparation and compositions thereof.
  • the avermectins and milbemycins form an important group of broad spectrum antiparasitic agents possessing anthelmintic, ectoparasiticidal, insecticidal, antibacterial and antifungal activity with application in the areas of animal and human health, agriculture and horticulture.
  • the avermectins are a group of macrolide compounds (previously referred to as C-076) isolated from the fermentation broth of an aver ectin producing strain of Streptomyces avermitilis such as those deposited strains ATCC 31267, ATCC 31271, ATCC 31272 as described in US patents 4310519 and 4429042.
  • European patents 214731 and 276103 disclose a related series of compounds differing from the C-076 compounds in the nature of the substituent at C-25.
  • the milbemycins form another group of related acrolides which are distinguished from the avermectins in lacking a sugar residue attached at C-13. Examples of such compounds are the B-41 series as described in UK patent 1390336, the LL-F28249 series described in European patent EP 170006, the E225 compounds described in European patent 254583 and the N787-182 compounds described in European patent application 334484.
  • a large number of publications describe compounds derived semi-synthetically from these fermentation products many of which possess useful antiparasitic activities. Some of this chemistry is reviewed by Davies, E . G . ' and Green, R.H. in Natural Product Reports (1986) , 2, 87-121.
  • Our European Patent Application 410615 describes a compound, herein designated UK-86956 of formula:
  • R 1 and R 2 are independently selected from H, Cj-C 8 alkyl, alkenyl, alkynyl, C 2 -C 8 alkanoyl, alkenoyl and alkynoyl, arylalkanoyl, arylcarbonyl and Cj-C 8 alkylsulphonyl and arylsulphonyl groups, wherein all these groups other than H may optionally be substituted with at least one hydroxy, Cj-Cg alkoxy, carboxy or halo group with the proviso that at least one of R 1 and R 2 are other than hydrogen.
  • the alkane, alkene and alkyne groups may be straight or branched-chain.
  • Halo means F, Cl, Br or I.
  • Another aspect of this invention provides compounds of formula (II) :
  • R 3 is oxo, optionally O-substituted oximino or methylene optionally substituted with cyano or a C,-C 8 alkyl, cycloalkyl, aryl, aralkyl or C,-C 8 alkoxycarbonyl group which groups may optionally be substituted by a halo, carboxy and/or other groups;
  • R 4 is 0-R 5 where R 5 is as defined for R 1 in formula (I) and the oxygen is attached at C-5 by a single bond or R 4 is oxo, optionally substituted imino or optionally O-substituted oximino, the broken line representing an double bond.
  • the oximino groups may be O-substituted by a wide variety of substituents including linear or branched Cj-Cg alkyl, alkenyl, alkynyl, trialkylsilyl and aralkyl groups which may themselves be substituted by halo, carboxy and/or other groups.
  • Compounds within this aspect of the invention include those in which R 3 is methylene and R 4 is OH or oximino and those in which R 3 is oxo and R 4 is hydroxy, methoxy or oximino.
  • a further aspect of the invention provides compounds of formula (III) :
  • R 1 is as defined for formula (I) and R 4 is oxo or oximino optionally substituted as for compounds of formula (II) .
  • the compounds of the invention have several asymmetric centres, the number of such centres depending on the nature of substituents R 1 -R 4 , and accordingly may exist as several pairs of stereoisomers.
  • Compound UK 86956, when prepared by fermentation of micro-organism ATCC 53928 is believed to have the following relative stereochemistry.
  • the compounds of the invention may be prepared by replacement of one or more of the hydroxy groups at the 5 and 22 positions of compound UK 86956 by the appropriate substituents. These substitutions may be carried out by means of reactions which are known in the art. However, in preparing these compounds it is necessary to react selectively at one of the 5 and 22 hydroxy groups. In some instances this may be achieved by choice of appropriate reagent, for example manganese dioxide which selectively converts the 5-hydroxy group to a 5-oxo group. Alternatively selective reaction may be achieved using suitable protecting groups such as acyl or silyl derivatives.
  • a particularly preferred protecting group is the tert-butyldi ethylsilyl group (TBDMS) which is readily removed when reguired using either an acid in a protic solvent such as methanol or with a fluoride ion source such as tetrabutylammonium fluoride dissolved in a suitable inert solvent such as tetrahydrofuran.
  • TDMS tert-butyldi ethylsilyl group
  • Alkylation of compound UK-86,956 may be achieved using conventional methodology such as treatment with an alkyl halide, preferably an alkyl iodide, in the presence of a silver salt or silver oxide.
  • an alkyl halide preferably an alkyl iodide
  • acylation or sulphonylation of UK-86,956 or its derivatives can be achieved using standard procedures for example by using an acyl or sulphonyl halide or anhydride in the presence of a base such as triethylamine, pyridine or dii ⁇ opropylamine.
  • Oxidation of the hydroxy group at C-22 may be carried out using a suitable oxidising agent such as dimethyls-ulphoxide/oxalyl chloride. Using these conditions the C-5 hydroxy group will also be oxidised if not protected for example using the TBDMS group.
  • the oxo group at C-5 or C-22 may be reduced to a hydroxy group although the stereochemical outcome of this reaction will depend on the choice of reducing agent. For example sodium borohydride will reduce either a C-5 or C-22 oxo group to a hydroxy group possessing substantially the same stereochemistry as that found in the UK-86,956 starting compound.
  • the oxo group at either C-5 or C-22 is a useful functional group for performing further semi-synthetic modification to the compounds.
  • R 6 is H or a substituent such as an alkyl, cyano, phenyl, alkanoyl or alkoxycarbonyl group.
  • the oxo group at C-5 and/or C-22 may be converted to an oximino group or O-substituted oximino group by reaction with an optionally O-substituted hydroxyla ine or salt thereof in a suitable solvent such as methanol, dioxane or water or combination thereof.
  • a suitable solvent such as methanol, dioxane or water or combination thereof.
  • 0- substituted oximino derivatives may alternatively be prepared by reaction of the oximino derivative with a suitable alkylating or acylating agent.
  • Oximino and substituted methylene derivatives may exist as E or Z- isomers and both stereoisomers are within the scope of this invention.
  • the compounds are effective in treating a variety of conditions caused by endoparasites including, in particular, helminthiasis which is most freguently caused by a group of parasitic worms described as nematodes and which can cause severe economic losses in swine, sheep, horses and cattle as well as affecting domestic animals and poultry.
  • the compounds are also effective against other nematodes which affect various species of animals including, for example, Dirofilaria and various parasites of dogs and cats which can infect humans including gastro-intestinal parasites such as Ancylostoma.
  • the compounds are also of value in treating ectoparasite infections including in particular arthropod ectoparasites of animals and birds such as ticks, mites, lice, fleas, blowfly, biting insects and migrating dipterous larvae which can affect swine, sheep, cattle and horses as well as affecting domestic animals and poultry.
  • ectoparasite infections including in particular arthropod ectoparasites of animals and birds such as ticks, mites, lice, fleas, blowfly, biting insects and migrating dipterous larvae which can affect swine, sheep, cattle and horses as well as affecting domestic animals and poultry.
  • the compounds are also insecticides active against household pests such as the cockroach, clothes moth, carpet beetle and the housefly as well as being useful against insect pests of stored grain and of agricultural plants such as spider mites, aphid ⁇ , caterpillars and against migratory orthopterans such as locusts.
  • the compounds of the invention possess a number of beneficial properties compared to similar compounds such as the natural product UK-86,956 in terms of their efficacy, phar acokinetics and toleration.
  • the benefits .. that arise from this unexpected combination of properties include efficacy against the important parasitic worms or arthropods afflicting livestock, domesticated animals or humans at lower doses than are currently employed for related compounds and, in addition, the ability to treat animals previously regarded as sensitive to this class of macrolide with a greater margin of safety.
  • the compounds of formula (I) , (II) or (III) are administered as a formulation appropriate to the specific use envisaged and to the particular species of host animal being treated and the parasite or insect involved.
  • the compounds are preferably administered by injection, either subcutaneously or intramuscularly, alternatively they may be administered orally in the form of a capsule, bolus, tablet, chewable tablet or liquid drench, or they may be administered as a pour-on formulation or as an implant.
  • Such formulations are prepared in a conventional manner in accordance with standard veterinary practice.
  • capsules, boluses or tablets may be prepared by mixing the active ingredient with a suitable finely divided diluent or carrier, additionally containing a disintegrating agent and/or binder such as starch, lactose, talc or magnesium stearate.
  • a drench formulation may be prepared by dispersing the active ingredient in an aqueous solution together with dispersing or wetting agents and injectable formulations may be prepared in the form of a sterile solution or emulsion.
  • a dose of from about 0.001 to 10 mg per Kg of animal body weight given as a single dose or in divided doses for a period of from 1 to 5 days will be satisfactory but of course there can be instances where higher or lower dosage ranges are indicated and such are within the scope of this invention.
  • the compounds may be administered with the animal feedstuff and for this purpose a concentrated feed additive or premix may be prepared for mixing with the normal animal feed.
  • the compounds are applied as sprays, dusts, pour-on formulations, emulsions and the like in accordance with standard agricultural practice.
  • the compounds may be administered as a pharmaceutically acceptable formulation of conventional type.
  • Example 8 The product of Example 8 may be converted to the corresponding 5-oxo and 5-oximino compounds by the methods described in Examples 1 and 2.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Agents antiparasitaires répondant à la formule (I), (II) ou (III), dans lesquelles R1 et R2, indépendamment l'un de l'autre, représentent H ou alkyle C1-8 éventuellement substitué, alcényle, alcynyle, alcanoyle C2-8, alcénoyle ou alcynoyle, arylalcanoyle, arylcarbonyle, ou arylsulfonyle ou alkylsulfonyle C1-8, où R1 et/ou R2 ne représentent pas H; R3 représente oxo, oximino éventuellement substitué par O ou méthylène éventuellement substitué; R4 représente oxo, imino éventuellement substitué, oximino éventuellement substitué par O ou -OR5 où R5 a la même notation que R1.
EP92923776A 1991-12-04 1992-11-24 Agents antiparasitaires Withdrawn EP0620819A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9125818 1991-12-04
GB919125818A GB9125818D0 (en) 1991-12-04 1991-12-04 Antiparasitic agents
PCT/EP1992/002697 WO1993011129A1 (fr) 1991-12-04 1992-11-24 Agents antiparasitaires

Publications (1)

Publication Number Publication Date
EP0620819A1 true EP0620819A1 (fr) 1994-10-26

Family

ID=10705714

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92923776A Withdrawn EP0620819A1 (fr) 1991-12-04 1992-11-24 Agents antiparasitaires

Country Status (5)

Country Link
EP (1) EP0620819A1 (fr)
JP (1) JPH07501800A (fr)
CA (1) CA2122614A1 (fr)
GB (1) GB9125818D0 (fr)
WO (1) WO1993011129A1 (fr)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8709327D0 (en) * 1987-04-21 1987-05-28 Beecham Group Plc Compounds
DE3888936T2 (de) * 1987-11-03 1994-07-21 Beecham Group Plc Zwischenprodukte für die Herstellung makrolider Antibiotika mit anthelmintischer Wirkung.
GB8905605D0 (en) * 1989-03-11 1989-04-26 Beecham Group Plc Novel compounds
GB8917064D0 (en) * 1989-07-26 1989-09-13 Pfizer Ltd Antiparasitic agent

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9311129A1 *

Also Published As

Publication number Publication date
GB9125818D0 (en) 1992-02-05
CA2122614A1 (fr) 1993-06-10
JPH07501800A (ja) 1995-02-23
WO1993011129A1 (fr) 1993-06-10

Similar Documents

Publication Publication Date Title
JP2505901B2 (ja) アベルメクチン誘導体
EP0259779B1 (fr) Dérivés des composés LL-F28249 comportant en position 23 un groupement oxo(céto) ou imine
CZ284849B6 (cs) Sloučeniny příbuzné milbemycinům a avermektinům, způsob a meziprodukty pro jejich výrobu a farmaceutické a veterinární prostředky na jejich bázi
US5169839A (en) Derivatives of 3'- and 3"-o-desmethyl avermectin compounds, compositions and methods of treating melmintic and parasitic infections
US5556868A (en) Antiparasitic avermectin and milbemycin derivatives
DE69033502T2 (de) Derivate von Avermectin und Milbemycin, die in Position 24 und 25 substituiert sind
EP0623137B1 (fr) Agents antiparasitaires
JPH0386885A (ja) アベルメクチン誘導体
US4886828A (en) Δ22 -derivatives of LL-F28249 compounds
AU603956B2 (en) Avermectin and milbemycin derivatives from streptomyces avermitiosis ATCC 31267, 31271 and 31272
US5677332A (en) Antiparasitic agents
US5883080A (en) Antiparastic auermectin derivatives
EP0241146A1 (fr) Composés de macrolides
US4849446A (en) 23-imino derivatives of 23-keto compounds
US4886829A (en) 23-Oxo (keto) and 23-imino derivatives of mono- and diepoxy LL-F28249 compounds
JPH0374397A (ja) アベルメクチン誘導体
CA1301750C (fr) Derives 13-desoxy-23-oxo(ceto) et 23-imino de composes 13-desoxy c-076-aglycone
JPH05202057A (ja) アベルメクチン分解生成物並びにその誘導体
AU680039B2 (en) Process and antiparasitic intermediates for doramectin
CA1317936C (fr) Derives mono- et diacyliques de composes du type ll-f28249
US5240915A (en) Avermectin derivatives
EP0620819A1 (fr) Agents antiparasitaires
CA1291129C (fr) Derives mono-et diepoxy de composes __-ll-f28249
CA1300617C (fr) Derives mono et diepoxides de composes de 23-deoxy-ll-f28249
JPH0219382A (ja) 開裂されたフラン環及び８ａヒドロキシ基を有する新規アベルメクチン類

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940509

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 19950118

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19950729